Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric Citrate for Hyperphosphatemia in CKD Patients on Hemodialysis
NCT03984760Phase 3Completed
- Sponsor
- Panion & BF Biotech Inc.
- Start
- Jun 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferric citrate in hyperphosphatemia (2 arms), sponsored by Panion & BF Biotech Inc. Primary endpoint: The change in serum phosphorus levels at 12 weeks. Started Jun 2019; status: completed.
02
Drugs
ferric citrate
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT03984760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03984760.